the aid library

LIST OPTIONS

Filter

1050

Sort by:

Direction:

Download (273)

View PDF (285)

Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030

World Health Organization WHO (2021) C_WHO

The road map sets global targets and milestones to prevent, control, eliminate or eradicate 20 diseases and disease groups as well as cross-cutting targets aligned with the Sustainable Development Goals. Three foundational pillars will support global efforts to achieve the targets: accelerate progra... more

Download (104)

View PDF (376)

Geographical, landscape and host associations of Trypanosoma cruzi DTUs and lineages

Izeta-Alberdi, A.; Ibarra-Cerdena, C.; Moo-llanes, D.; Ramsey,J. BMC Part of Springer Nature (2016) CC

Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio... more

Download (85)

View PDF (340)

iagnostic Gaps and Recommendations for Human African Trypanosomiasis: Assessment of User Needs, Use Cases, and the Diagnostic Landscape

PATH (2016) C2

In support of the London Declaration goals, PATH aims to catalyze engagement of the diagnostics industry and product development efforts. As part of this work, PATH conducted a diagnostic landscape analysis to identify gaps and evaluated current and nascent HAT diagnostics that may provide solutions... more

Download (164)

View PDF (201)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (76)

View PDF (441)

Leptospirosis in sugarcane plantation and fishing communities in Kagera northwestern Tanzania

Mgode, G.; Japhary, M.; Mhamphi, G. et al. PLoS Neglected Tropical diseases (2019) CC

Leptospirosis is a bacterial zoonotic disease of worldwide importance, though relatively neglected in many African countries including sub Saharan Africa that is among areas with high burden of this disease. The disease is often mistaken for other febrile illnesses such as dengue, malaria, rickettsi... more

Download (116)

View PDF (347)

Taenia solium Use of existing diagnostic tools in public health programmes

World Health Organization WHO; Institutional Repository for Information Sharing iris (2022) C_WHO

Taeniasis and cysticercosis caused by the parasite T. solium affect vulnerable populations, mainly in Latin America, sub-Saharan Africa and Asia, where pigs (the intermediate host) roam free and poor sanitation allows pigs access to human faeces.

Download (79)

View PDF (254)

Taenia solium taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa

Braae, U.; Saarnak, C.; Mukaratirwa, S. et al. Parasites and Vectors (2015) CC

The major neglected tropical diseases, Taenia solium taeniosis/cysticercosis and schistosomiasis caused by Schistosoma mansoni or S. haematobium are presumed to be widely distributed in Africa. Taenia solium taeniosis/ cysticercosis has been reported as an emerging disease in different regions of Af... more

Download (158)

View PDF (192)

Вывести из забвения для достижения. Целей в области устойчивого развития Механизм мониторинга и оценки прогресса для д орожной карты по борьбе с забытыми тропическими болезнями на 2021–2030 гг

World Health Organization WHO (2021) C_WHO

В дорожной карте по борьбе с забытыми тропическими болезнями на 2021–2030 гг. («дорожная карта») определены глобальные цели и основные этапы в отношении борьбы с 20 бол�... more

Download (104)

View PDF (118)

WHO's Response to the Ukraine Crisis. Interim Report. February to June 2022

World Health Organization (WHO) (2022) C_WHO

The military offensive by the Russian Federation in Ukraine which began February 2022 has triggered one of the world’s fastest-growing displacement and humanitarian crisis, with geopolitical and economic ripples felt across the globe. The ongoing war has caused large-scale disruptions to the deliv... more

Download (94)

View PDF (106)

WHO South Sudan Annual Report 2022

World Health Organisation (WHO) (2023) C_WHO

A lot has happened this year. While we continued to tackle the COVID-19 pandemic, we were hit by disease outbreaks and humanitarian crises. Yet, despite these challenges, we marched on, resolute in resolving critical health systems issues to increase access to quality healthcare services. To furth... more

Download (166)

View PDF (177)

Global vaccine market report 2022: a shared understanding for equitable access to vaccines

World Health Organisation (WHO) (2023) C_WHO

The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized i... more

Download (124)

View PDF (139)

Medical treatment of cystic echinococcosis: systematic review and meta-analysis

Velasco-Tirado, V.; Alonso-Sardón, M.; Lopez-Bernus, A. et al BMC Infectious Diseases (2018) C2

Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t... more

Download (192)

View PDF (171)

Target product profiles for animal plasma-derived antivenoms: antivenoms for treatment of snakebite envenoming in sub-Saharan Africa

World Health Organisation (WHO) (2023) C_WHO

This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document: Broad spectrum Pan-African polyvalent antivenoms: products ... more

Download (100)

View PDF (115)

Annual Report of the WHO Country Office in Zimbabwe, 2022

World Health Organisation (WHO) (2023) C_WHO

This report highlights the work of the World Health Organization (WHO) in Zimbabwe towards contributing to the triple billion targets in the context of the Sustainable Development Goals (SDGs

Download (77)

View PDF (86)

ACT-A - Urgent Priorities & Financing Requirements at 10 November 2020

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2020) CC

Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (107)

View PDF (91)

An economic investment case & financing requirements

ACT-Accelerator: An economic investment case & financing requirements (2021) C_WHO

This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm... more

Download (23)

View PDF (22)

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aday A.W.; Matsushita, K. Circulation Research (2021) CC

Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ... more

Download (106)

View PDF (116)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more

Download (24)

View PDF (21)

Kenya Asthma Management Guideline

Ministry of Health (2021) CC

Bonchial asthma is the most common chronic respiratory disease in the world. In Kenya, it has been estimated that about 7.5% of the Kenyan population, nearly 4 million people, are currently living with asthma. Many cases tend to be underdiagnosed and undertreated which leads to high levels of morbid... more